Fig. 5: Upregulated DKK1 sustains CRC tumor growth and associates with oxaliplatin resistance.
From: DKK1 as a chemoresistant protein modulates oxaliplatin responses in colorectal cancer
A Growth curves of xenograft tumors derived from CA01 cells stably expressing SP-GFP or DKK1-GFP. The tumor-bearing mice were treated with mock (n = 6) or administered 5 mg/kg oxaliplatin once per week (n = 6) for 3 weeks. Data are mean ± SEM. B Curves of relative tumor volume in xenograft tumors from (A). Relative tumor volume was calculated using oxaliplatin-treated tumor volume/mock-treated tumor volume. **p < 0.01, ***p < 0.001. Data are mean ± SEM. C Relative tumor volume at day 17, as described in (B), was calculated as oxaliplatin-treated volume/mock-treated volume × 100%. **p < 0.01. Data are mean ± SEM (n = 6). D The percentage of Ki67+ cells in CA01 xenograft tumors are shown in (A). A total of 2000 cells were calculated in each tumor section. ***p < 0.001, n.s. not significant. Data are mean ± SEM (n = 6). E The percentage of TUNEL+ cells in CA01 xenograft tumors is shown in (A). A total of 2000 cells were calculated in each tumor section. ***p < 0.001, n.s. not significant. Data are mean ± SEM (n = 6).
